Clinical Trial Update: Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bortezomib, dexamethasone, and zoledronic acid for bone disease in relapsed multiple myeloma; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: University of Athens | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-08-05